

dysfunction (cognitive endophenotypes) may help focus the search for genetic contributions. Such markers should be present in people at risk of developing OCD in the absence of clinical symptoms. In prior work, OCD patients showed impairment on tests of response inhibition and cognitive flexibility (Chamberlain et al., 2005, 2006).

**Methods:** First-degree relatives of OCD patients, patient probands, and matched healthy volunteers without a family history of OCD undertook neuropsychological assessment (n=20 per group).

**Results:** Compared to matched controls without a family history of OCD, unaffected first-degree relatives of OCD patients showed impaired response inhibition ( $p < 0.05$ ) and cognitive flexibility ( $p < 0.05$ ). These deficits were comparable to those in the patients themselves.

**Conclusions:** Brain-based cognitive markers of inhibitory functions may be of utility in the search for OCD endophenotypes. Examination of relationships between these abnormalities, genetics, and structural/functional brain changes, will help to elucidate aetiological contributions to OCD and putative spectrum disorders.

## P252

Relapse prevention in patients with obsessive-compulsive disorder (OCD)

N. Fineberg<sup>1</sup>, O. Lemming<sup>2</sup>, B. Tonnoir<sup>2</sup>, D. Stein<sup>3</sup>.  
<sup>1</sup> *Postgraduate Medical School, University of Hertfordshire, Hatfield, United Kingdom* <sup>2</sup> *H. Lundbeck A/S, Copenhagen, Denmark* <sup>3</sup> *Department of Psychiatry, University of Cape Town, Cape Town, South Africa*

**Purpose:** To compare the efficacy of escitalopram 10 or 20 mg/day with placebo in preventing relapse during 24 weeks in outpatients with obsessive-compulsive disorder (OCD) who had responded to an initial 16-week open-label treatment with escitalopram.

**Methods:** A multinational, randomised, double blind, placebo-controlled, flexible to fixed dose relapse prevention study with escitalopram in outpatients with OCD. The study consisted of a 16-week open-label period with 10 to 20 mg escitalopram followed by a 24 week double blind, placebo-controlled period, and a 1 week taper period. Patients who had responded to treatment ( $\geq 25\%$  decrease in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score) by the end of the 16-week open-label period were eligible for randomisation to either escitalopram or placebo for a further 24 weeks.

**Results:** 468 patients with OCD were treated with open-label escitalopram (10 mg or 20 mg) for 16 weeks. There were 320 responders (68%) who were randomised to change to placebo (n=157) or to continue with escitalopram (at the assigned dose) for further 24 weeks (n=163). The primary analysis (time to relapse) showed a clear beneficial effect of escitalopram relative to placebo (log-rank test,  $p < 0.001$ ). The proportion of patients who relapsed was statistically significantly higher in the placebo group (52%) than in the escitalopram group (23%) ( $p < 0.001$ , chi-square test). The risk of relapse was 2.74 times higher for placebo- than for escitalopram-treated patients (chi-square test,  $p < 0.001$ ). Escitalopram was well tolerated.

**Conclusion:** Escitalopram was effective in preventing relapse of OCD and was well tolerated as continuation treatment.

## P253

The treatment of obsessive-compulsive disorder with escitalopram

D.J. Stein<sup>1</sup>, B. Tonnoir<sup>2</sup>, E.H. Reines<sup>2</sup>, E.W. Andersen<sup>2</sup>, N. Fineberg<sup>3</sup>. <sup>1</sup> *Department of Psychiatry, University of Cape Town, Cape Town, South Africa* <sup>2</sup> *H. Lundbeck A/S, Copenhagen,*

*Denmark* <sup>3</sup> *Postgraduate Medical School, University of Hertfordshire, Hatfield, United Kingdom*

**Purpose:** The efficacy and tolerability of escitalopram in obsessive-compulsive disorder (OCD) were investigated in a 24-week, randomised, placebo-controlled, active-referenced, double blind study.

**Methods:** 466 adults with OCD were randomised to escitalopram 10mg/day (N=116), escitalopram 20mg/day (N=116), paroxetine 40mg/day (N=119), or placebo (N=115) for 24 weeks. The pre-specified primary efficacy endpoint was the mean change in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) total score from baseline to Week 12 based on the intent-to-treat population and last observation carried forward (LOCF) using analysis of variance (ANCOVA).

**Results:** Escitalopram 20mg/day was superior to placebo on the primary endpoint. After 12 weeks, on the primary efficacy endpoint, there was a statistically significant difference from placebo for 20mg escitalopram and paroxetine. In the escitalopram 20mg/day group, the Y-BOCS total score was significantly lower than in the placebo group as early as Week 6. At Week 24, the proportion of remitters (Y-BOCS  $\leq 10$ , LOCF, pre-defined) was significantly greater ( $p < 0.05$ ) for 20mg escitalopram (41.2%) than placebo (27.4%), but not for 10mg escitalopram (36.6%) or paroxetine (37.9%). The response rate ( $\geq 25$  decrease from baseline Y-BOCS, LOCF, pre-defined) was significantly greater than placebo (50.4%) for 20mg escitalopram (70.2%) and paroxetine (67.2%). Statistically significantly more patients withdrew from the placebo group (18%) due to lack of efficacy, than paroxetine (8%) or escitalopram 20mg/day groups (6%). More paroxetine-treated patients withdrew due to adverse events than escitalopram- or placebo-treated patients.

**Conclusion:** Escitalopram was efficacious and well tolerated in the treatment of OCD, with 20mg escitalopram showing statistically significant superiority at the primary efficacy endpoint.

## P254

Amis subito: Assessment, measurement, intervention and studies for the prevention of suicidal behaviour in individuals, inclined to gamble excessively

S. Gougler<sup>1</sup>, M. Rihs-Middel<sup>1</sup>, M. Andronicos<sup>1</sup>, J. Battisti<sup>1</sup>, N. Cornuz<sup>1</sup>, L. Aufreire<sup>1</sup>, O. Simon<sup>1</sup>, J. Besson<sup>2</sup>. <sup>1</sup> *Center for Pathological Gambling, Community Psychiatry Services, Department of Adult Psychiatry, Lausanne, Switzerland* <sup>2</sup> *Community Psychiatry Services- Department of Adult Psychiatry, Lausanne, Switzerland*

**Background and aim:** Actually, the suicidal risk in people with gambling problems is insufficiently evaluated; this risk is all the more hard to specify within a population which underreports gambling behaviour and associated co-morbidities. Estimations of suicidal behaviour vary between studies, suicide attempts were observed in 4% to 40% of gamblers studied. Suicidal thoughts were reported for 25% to 92% of people with gambling problems. 64% of gamblers that committed suicide did neither inform family or friends nor health professionals about their suicidal intents. In the context of a pilot study, we wish to study suicidal behaviour in people with gambling problems.

**Method:** The goal of the study consists in the early identification of gambling problems associated with suicidal behaviour. A short intervention, specifically targeted towards the prevention of suicide will be compared with the current treatment for gambling problems. Gambling and suicidal behaviour will be monitored over 6 meetings during 12 months.